Gew59, I am looking forward to updates in the studies of PKTX’s AAGP being carried by three different groups of scientists along with ProtoKinetix itself. The three groups of scientists that are involved in studying the effects of AAGP are University of Alberta (UofA), University of British Columbia (UofBC) and Proactive Immune Sciences (PIS).
Each of the group are involved in their own area of expertise.
UofA is studying:
1. Diabetes (study started in February 2017) The study is treating islet cells prior to transplantation into human test subjects.
2. Kidney Ischemia (anticipated start date 4th quarter 2017) Ischemia is a condition that occurs when blood flow to cells, tissues or organs is severely restricted.
3. Normothermic Liver Perfusion (start date to be determined) Normothermic (body temperature), ex vivo (outside the body) liver perfusion (method of irrigation) is an innovative therapy.
UofBC is studying:
1. Retinal Cell Replacement (started June 2016) to determine whether AAGP can help improve the survival of stem cells that are currently being used in human trials to treat retinal blindness.
2. Monoclonal Antibody Production (anticipated start date 4th quarter 2017) Monoclonal antibodies are antibodies that are made by identical immune cells that are all clones of a unique parent cell.
PIS is studying:
1. Immune Cell Cryopreservation Recovery (started June 2017 – anticipated end date 4th quarter 2017) Immune based interventions represent one of the fastest growing, most promising areas of personal medicine. This is particularly true for cancer, which is largely a disease of immune failure.
PKTX is studying:
1. Bone Marrow Recovery (Preliminary stage) Bone marrow is a flexible tissue in the interior of bones.
2. Cord Blood Preservation (preliminary stage) Cord blood is the blood left in the umbilical cord and placenta immediately after a baby is born.
3. Ischemic Stroke Repair (anticipated start 4th quarter 2017) Ischemic Stroke is usually associated with severe disabilities, high recurrence rate and other poor outcomes.
These are all ongoing studies with most out of PKTX’s control. The progress and completion are in the hands of the scientists who are preforming the studies. The significance is, they are all using PKTX’s AAGP ™.
ProtoKinetix Inc., will have success on a number of studies. It is just a matter of time. IMHO
